At a glance
An albumin-binding GHRH analogue studied for prolonged endocrine activity.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The cited research examines GH and IGF-1 responses. Changes in hormone measurements do not independently establish improvements in strength, recovery or longevity.[3][4][10]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of CJC-1295 DAC.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 5 mg · 1 source tables
Standard / Gradual Approach (2 mL = 2500 mcg/mL)
| Week | Per-Injection Dose (mcg) | Units (per injection) (mL) | Weekly Total |
|---|---|---|---|
| Weeks 1–2 | 300 mcg (0.3 mg) | 12 units (0.12 mL) | 600 mcg/week |
| Weeks 3–4 | 500 mcg (0.5 mg) | 20 units (0.20 mL) | 1000 mcg/week |
| Weeks 5–6 | 750 mcg (0.75 mg) | 30 units (0.30 mL) | 1500 mcg/week |
| Weeks 7–12 | 1000 mcg (1 mg) | 40 units (0.40 mL) | 2000 mcg/week |
Frequency: Inject twice weekly subcutaneously (e.g., Monday/Thursday or Tuesday/Friday). The extended 6–8-day half-life from the DAC modification supports less frequent dosing compared to non-DAC GHRH analogs[12][13]. Once-weekly dosing is also studied; adjust frequency based on protocol requirements. For ≤10-unit (≤0.10 mL) administrations, consider 30- or 50-unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the twice-weekly regimen.
- Goal: Support sustained GH and IGF-1 elevation for research into GH-axis effects[12].
- Schedule: Twice-weekly subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
- Dose Range: 300–1000 mcg per injection with gradual titration.
- Reconstitution: 2.0 mL per 5 mg vial (2.5 mg/mL) for accurate unit measurements.
- Storage: Lyophilized frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested twice-weekly titration approach.
- Start: 300 mcg per injection twice weekly; increase by ~250 mcg every 2 weeks as tolerated.
- Target: 750–1000 mcg per injection by Weeks 5–12.
- Frequency: Twice per week (subcutaneous), spaced 3–4 days apart.
- Cycle Length: 8–12 weeks; optional extension to 16 weeks.
- Timing: Consistent timing (e.g., evenings); rotate injection sites.
Preparation
Reconstitution Steps
- Draw 2.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality.
- Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); stable for 2–4 weeks; avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best-practice resources[15][16].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45–90° into subcutaneous tissue[15][18].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[15].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[16][17].
- Do not rub or massage the injection site after administration[18].
Materials & quantity planning
Source materials checklist · 5 mg
Plan based on an 8–16 week twice-weekly protocol with gradual titration.
-
Peptide Vials (CJC-1295 DAC, 5 mg each):
- 8 weeks ≈ 3 vials (~10.2 mg total)
- 12 weeks ≈ 4 vials (~18.2 mg total)
- 16 weeks ≈ 6 vials (~26.2 mg total)
-
Insulin Syringes (U-100):
- Per week: 2 syringes (twice weekly)
- 8 weeks: 16 syringes
- 12 weeks: 24 syringes
- 16 weeks: 32 syringes
-
Bacteriostatic Water (10 mL bottles): Use ~2.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 6 mL → 1 × 10 mL bottle
- 12 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- 16 weeks (6 vials): 12 mL → 2 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each injection.
- Per week: 4 swabs (2 per injection × 2 injections)
- 8 weeks: 32 swabs → recommend 1 × 100-count box
- 12 weeks: 48 swabs → recommend 1 × 100-count box
- 16 weeks: 64 swabs → recommend 1 × 100-count box
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 5 mg per vial and 2 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 02
Research publication
Clinical Pharmacology & Therapeutics — DAC technology: albumin-binding for extended peptide half-life (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 04
Research publication
PubMed — Body composition and quality of life in adults with GH deficiency; effects of GH replacement (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 05
Research publication
PubMed — Physiology of growth hormone secretion during sleep (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 06
Source document
Bachem — Handling and storage guidelines for peptides (opens in a new tab)www.bachem.com
Back to overview ↑ - 07
Public health resource
CDC — Preventing unsafe injection practices and clinical safety guidelines (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
MedlinePlus — Subcutaneous (SQ) injections: technique, site selection, and rotation (opens in a new tab)medlineplus.gov
Back to overview ↑ - 09
Source document
Endocrine Reviews — GHRH analogs and preservation of pulsatile GH secretion patterns (opens in a new tab)academic.oup.com
Back to overview ↑ - 10
Research publication
PubMed — Effect of tesamorelin on visceral fat in HIV-infected patients: randomized clinical trial (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 11
- 12
Research publication
J Clin Endocrinol Metab (2006) — Teichman SL et al. Prolonged stimulation of GH and IGF-1 by CJC-1295 in healthy adults (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 13
Research publication
J Clin Endocrinol Metab (2006) — Ionescu M et al. Pulsatile GH secretion persists during continuous CJC-1295 stimulation (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 14
Public health resource
StatPearls (NCBI Bookshelf) — Brinkman JE et al. Physiology, Growth Hormone (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 15
- 16
Source document
Johns Hopkins Arthritis Center — How to give a subcutaneous injection (patient guidance) (opens in a new tab)www.hopkinsarthritis.org
Back to overview ↑ - 17
Public health resource
StatPearls (NCBI Bookshelf) — Regular Insulin: subcutaneous administration and site rotation (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 18
- 19
Research publication
Postgrad Med J (2006) — Ayuk J, Sheppard MC. Growth hormone and its disorders (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑ - 20
Research publication
Am J Physiol Endocrinol Metab (2006) — Alba M et al. Once-daily CJC-1295 normalizes growth in GHRH knockout mouse (opens in a new tab)pubmed.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.